Free Trial
OTCMKTS:EMMA

Emmaus Life Sciences (EMMA) Stock Price, News & Analysis

Emmaus Life Sciences logo
$0.03
-0.01 (-26.95%)
(As of 11/4/2024 ET)

About Emmaus Life Sciences Stock (OTCMKTS:EMMA)

Key Stats

Today's Range
$0.03
$0.03
50-Day Range
$0.00
$0.05
52-Week Range
$0.00
$0.14
Volume
181,130 shs
Average Volume
35,549 shs
Market Capitalization
$1.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

Emmaus Life Sciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
3rd Percentile Overall Score

EMMA MarketRank™: 

Emmaus Life Sciences scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Emmaus Life Sciences is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Emmaus Life Sciences is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Emmaus Life Sciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Emmaus Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Emmaus Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Emmaus Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Emmaus Life Sciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Emmaus Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Emmaus Life Sciences this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Emmaus Life Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    35.00% of the stock of Emmaus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.42% of the stock of Emmaus Life Sciences is held by institutions.

  • Read more about Emmaus Life Sciences' insider trading history.
Receive EMMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

EMMA Stock News Headlines

The Crypto That’s Making Wall Street Sweat
The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.
Emmaus Life Sciences appoints new board member
See More Headlines

EMMA Stock Analysis - Frequently Asked Questions

Emmaus Life Sciences' stock was trading at $0.1001 at the beginning of the year. Since then, EMMA shares have decreased by 72.9% and is now trading at $0.0271.
View the best growth stocks for 2024 here
.

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) issued its earnings results on Tuesday, September, 10th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business earned $5.38 million during the quarter.

Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Humanigen (HGEN), Matinas BioPharma (MTNB), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Acasti Pharma (ACST), Actinium Pharmaceuticals (ATNM) and Entasis Therapeutics (ETTX).

Company Calendar

Last Earnings
9/10/2024
Today
11/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:EMMA
Employees
60
Year Founded
N/A

Profitability

Net Income
$-3,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$29.60 million
Book Value
($0.69) per share

Miscellaneous

Free Float
41,513,000
Market Cap
$2.24 million
Optionable
Not Optionable
Beta
6.50
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (OTCMKTS:EMMA) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners